Felipe García, Carmen Vidal, Montserrat Plana, Anna Cruceta, M. Theresa Gallart, Tomas Pumarola, Jose M. Miro and Jose M. Gatell We report the evolution of chronic infection with human ...
Most women living with HIV achieved an immunologic response after 2 years of initiating antiretroviral therapy. A higher baseline HIV viral load increased the odds of an immunologic response in women ...
The decrease in CD4 cells during HIV infection seems to be driven by immune activation, which does not always correlate with viral load. Experienced clinicians are all too familiar with the ...
A CD4+ count below 200 cells/μL, advanced age at antiretroviral therapy initiation, and protease inhibitor use were associated with low-level viremia and increased risk for virologic failure among ...
CD4 tests are strongly recommended as the preferred method to identify advanced HIV disease among people living with HIV, the ...
MedPage Today on MSN
Once-Weekly Oral Combo for HIV Maintains High Rates of Virologic Suppression
A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...
In modified intention-to-treat analysis, time to linkage to care significantly less for people with HIV in intervention group ...
A phase 2 randomized study evaluating the efficacy and safety of once-weekly oral islatravir plus lenacapavir (ISL+LEN) in ...
Clinical Trials Arena on MSN
Gilead’s HIV ART combo deemed non-inferior in second phase III trial
"Gilead’s HIV ART combo deemed non-inferior in second Phase III trial" was originally created and published by Clinical ...
CD4 tests is strongly recommended as the preferred method to identify advanced HIV disease among people living with HIV, said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results